Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Galderma S.A. Snapshot 7
Galderma S.A. Overview 7
Key Information 7
Key Facts 7
Galderma S.A. – Research and Development Overview 8
Key Therapeutic Areas 8
Galderma S.A. – Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products – Monotherapy 11
Pipeline Products – Combination Treatment Modalities 12
Galderma S.A. – Pipeline Products Glance 13
Galderma S.A. – Late Stage Pipeline 13
Phase III Products/Combination Treatment Modalities 13
Galderma S.A. Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Galderma S.A. – Drug Profiles 15
CD 2027 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
CD07223 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
CD07805/47 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
CD2475/101 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
CD5024 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Clobetasol Propionate + Ketoconazole 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
COL-101 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Differin + Tetralysal 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Epiduo + Doxycycline 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Galderma S.A. – Pipeline Analysis 26
Galderma S.A. – Pipeline Products by Therapeutic Class 26
Galderma S.A. – Pipeline Products By Target 28
Galderma S.A. – Pipeline Products by Route of Administration 29
Galderma S.A. – Pipeline Products By Mechanism of Action 30
Galderma S.A. – Recent Pipeline Updates 32
Galderma S.A. - Dormant Projects 33
Galderma S.A. - Discontinued Pipeline Products 34
Discontinued Pipeline Product Profiles 34
Incyclinide 34
Galderma S.A. – Company Statement 35
Galderma S.A. – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Galderma S.A. - Key Manufacturing Facilities 37
Galderma S.A., Recent Developments 38
Galderma S.A.- Press Release 38
Mar 16, 2012: Galderma Completes Phase III Trials Of Investigational Drug Targeting Facial Erythema Of Rosacea 38
Mar 14, 2012: Combined Therapy Of Acne Medications Offers New Treatment Option For Patients, Henry Ford Hospital Study Reports 38
Sep 21, 2009: Galderma Receives Approval For Azzalure For Treatment Of Glabellar Lines In Spain 39
Jun 26, 2009: Galderma's Azzalure Receives Approval For Treatment Of Glabellar Lines In Germany 40
Mar 30, 2009: Galderma's Azzalure Receives Approval For Treatment Of Glabellar Lines In France 40
Mar 12, 2009: Galderma's Azzalure Receives Approval For Treatment Of Glabellar Lines In UK 41
Feb 02, 2009: Ipsen And Galderma Receive Approval For Azzalure In 15 European Countries 41
Financial Deals Landscape 43
Galderma S.A., Deals Summary 43
Galderma S.A., Pharmaceuticals & Healthcare, Deal Details 44
Asset Transactions 44
Galderma Acquires Metvix And Aktilite From PhotoCure 44
Galderma Labs Acquires Oracea Rights From MediGene 46
Partnerships 48
AstraZeneca Enters Into Research And Development Agreement With Galderma Pharma 48
NovaBay Expands Co-Development Agreement With Galderma 50
Foamix Extends Collaboration With Galderma Pharma 52
NovaBay Enters Into An Agreement With Galderma 53
Foamix And Galderma Sign An Agreement 55
Ipsen Extends Agreement With Galderma 56
Shionogi Signs Agreement With Galderma 57
Licensing Agreements 58
Galderma Enters Into A Licensing Agreement With PhotoCure 58
Galderma Expands Licensing Agreement With ZARS Pharma 59
Galderma Enters Into Licensing Agreement With ZARS Pharma 60
Ipsen Signs An Agreement With Galderma 61
Anika Therapeutics Enters Into Licensing Agreement With Galderma Pharma 62
Acquisition 63
Galderma Acquires Q-Med 63
Galderma Acquires CollaGenex Pharma 66
Appendix 68
Methodology 68
Coverage 68
Secondary Research 68
Primary Research 68
Expert Panel Validation 68
Contact Us 69
Disclaimer 69

List of Tables
List of Tables
Galderma S.A., Key Information 7
Galderma S.A., Key Facts 7
Galderma S.A. – Pipeline by Indication, 2012 9
Galderma S.A. – Pipeline by Stage of Development, 2012 10
Galderma S.A. – Monotherapy Products in Pipeline, 2012 11
Galderma S.A. – Combination Treatment Modalities in Pipeline, 2012 12
Galderma S.A. – Phase III, 2012 13
Galderma S.A. – Phase II, 2012 14
Galderma S.A. – Pipeline By Therapeutic Class, 2012 27
Galderma S.A. - Pipeline By Target, 2012 28
Galderma S.A. – Pipeline By Route of Administration, 2012 29
Galderma S.A. – Pipeline Products By Mechanism of Action, 2012 31
Galderma S.A. – Recent Pipeline Updates, 2012 32
Galderma S.A. - Dormant Developmental Projects,2012 33
Galderma S.A. - Discontinued Pipeline Products, 2012 34
Galderma S.A., Other Locations 36
Galderma S.A., Key Manufacturing Facilities 37
Galderma S.A., Deals Summary 43
Galderma Acquires Metvix And Aktilite From PhotoCure 44
Galderma Labs Acquires Oracea Rights From MediGene 46
AstraZeneca Enters Into Research And Development Agreement With Galderma Pharma 48
NovaBay Expands Co-Development Agreement With Galderma 50
Foamix Extends Collaboration With Galderma Pharma 52
NovaBay Enters Into An Agreement With Galderma 53
Foamix And Galderma Sign An Agreement 55
Ipsen Extends Agreement With Galderma 56
Shionogi Signs Agreement With Galderma 57
Galderma Enters Into A Licensing Agreement With PhotoCure 58
Galderma Expands Licensing Agreement With ZARS Pharma 59
Galderma Enters Into Licensing Agreement With ZARS Pharma 60
Ipsen Signs An Agreement With Galderma 61
Anika Therapeutics Enters Into Licensing Agreement With Galderma Pharma 62
Galderma Acquires Q-Med 63
Galderma Acquires CollaGenex Pharma 66

List of Figures
List of Figures
Galderma S.A. – Pipeline by Indication, 2012 9
Galderma S.A. – Pipeline by Stage of Development, 2012 10
Galderma S.A. – Monotherapy Products in Pipeline, 2012 11
Galderma S.A. – Combination Treatment Modalities in Pipeline, 2012 12
Galderma S.A. – Pipeline By Therapeutic Class, 2012 26
Galderma S.A. - Pipeline By Target, 2012 28
Galderma S.A. – Pipeline By Route of Administration, 2012 29
Galderma S.A. - Pipeline Products By Mechanism of Action, 2012 30